

# Emerging Treatment Strategies for Nonalcoholic Steatohepatitis On the Road to Resolution?

**SATURDAY, 24 JUNE 2023 | 12:45–13:45 CET**

REED MESSE WIEN EXHIBITION AND CONGRESS CENTER  
MESSEPLATZ 1, 1021 VIENNA, AUSTRIA | **ROOM:** LEHAR 1-2



## FACULTY



**Stephen A. Harrison, MD**  
Visiting Professor of Hepatology  
Radcliffe Department of Medicine  
University of Oxford  
Oxford, United Kingdom  
Chairman and Founder,  
Pinnacle Clinical Research  
Chairman and Co-Founder,  
Summit Clinical Research  
San Antonio, Texas, United States



**Elisabetta Bugianesi, MD, PhD**  
Professor of Gastroenterology  
Department of Medical Sciences  
University of Turin  
Turin, Italy



**Vlad Ratziu, MD, PhD**  
Professor of Hepatology  
Sorbonne University  
ICAN Institute for Cardiometabolism  
and Nutrition  
Paris, France



For more information visit:

[www.medscape.org/symposium/nash-thyroid-hormone-liver-disease](https://www.medscape.org/symposium/nash-thyroid-hormone-liver-disease)

**INTEGRATED SYMPOSIUM OF THE INTERNATIONAL LIVER CONGRESS™ 2023, 59TH ANNUAL MEETING  
OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER.**

## AGENDA

12:45

### Welcome and Introductions

Stephen A. Harrison, MD

12:48

### *NASH Pathophysiology and Noninvasive Diagnostic Tools: Latest Developments*

Elisabetta Bugianesi, MD, PhD

13:03

### *Intervening in the Disease Process: Emerging Treatment Concepts for NASH*

Stephen A. Harrison, MD

13:23

### *The Patient With NASH and Fibrosis: A Vision for Future Clinical Care*

Vlad Ratziu, MD, PhD

13:38

### *The Central Role of the Hepatologist in NASH Management*

### Audience Q&A

All Faculty

## TARGET AUDIENCE

This activity is intended for hepatologists/gastroenterologists involved in the management of nonalcoholic steatohepatitis (NASH).

## LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Pathophysiology of NASH as a progressive metabolic liver disease linked to insulin resistance and obesity
- Requirement to screen individuals at risk of NASH
- Mode of action and clinical outcomes of emerging treatment options for NASH

## ACCREDITATION STATEMENT


Medscape



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



For more information visit:

[www.medscape.org/symposium/nash-thyroid-hormone-liver-disease](http://www.medscape.org/symposium/nash-thyroid-hormone-liver-disease)